TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3278876
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms levothyroxine (T4) daily (group I, n = 35)
Study: 3278876
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms levothyroxine and 130.8 micrograms potassium iodide daily (group II, n = 39)
Study: 3278876
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms iodide daily (prophylactic administration after initial treatment)
Study: 29385323
Drug: LY3016859 (LY)
Normalized name: LYS
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3016859 (LY) administered intravenously (0.1-750 mg) or subcutaneously (50 mg)
Study: 29385323
Drug: LY3016859 (LY)
Normalized name: LYS
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3016859 (LY) administered intravenously (10-750 mg)
Study: 29385323
Drug: LY3016859 (LY)
Normalized name: LYS
DrugBank: Fepixnebart (DB19079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3016859 (LY) administered intravenously (50-750 mg)
Study: 27721247
Drug: Oxycodone 1
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Study: 27721247
Drug: Dezocine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Study: 27721247
Drug: Oxycodone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone group
Study: 18547955
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of r-hGH
Study: 31477545
Drug: Fixed-combination, low-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination, low-dose, triple-pill antihypertensive therapy (amlodipine, telmisartan, chlorthalidone)
Study: 25466805
Drug: Nebulized amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized amphotericin B (2.5 mg)
Study: 25466805
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (0.5 mg)
Study: 21464720
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg for 4 weeks
Study: 21464720
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg for 4 weeks
Study: 18769636
Drug: Various pharmacological
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacological treatment modalities for TBI
Study: 10709673
Drug: Exisulind (Sulindac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind (Sulindac sulfone) 200 mg, 300 mg, or 400 mg twice daily for six months
Study: 10709673
Drug: Exisulind (Sulindac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exisulind (Sulindac sulfone) at all dose levels
Study: 7596054
Drug: Arm IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm IV: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐fluorouracil (5‐FU) 200 mg/body/day p.o. for six months
Study: 7596054
Drug: Arm V:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm V: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Study: 7596054
Drug: Arm I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐FU 200 mg/body/day p.o. for six months
Study: 7596054
Drug: Arm II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm II: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Study: 7596054
Drug: Dukes C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukes C patients in Arm II: postoperative treatment
Study: 29949473
Drug: Heat-stable carbetocin
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable carbetocin (100 μg)
Study: 26908570
Drug: Sensor augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor augmented pump therapy with low glucose insulin suspension
Study: 16737798
Drug: Neurocognitive Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive Enhancement Therapy with Work Therapy (NET+WT)
Study: 16737798
Drug: Work Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work Therapy only (WT only)
Study: 10371095
Drug: Terfenadine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (1 mg/kg per body weight per day)
Study: 9049968
Drug: VACPE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACPE regimen (vincristine 2 mg d1, adriamycin 25 mg/m2 d1-3, cyclophosphamide 800 mg/m2 d1, prednisone 60 mg/m2 d1-7, etoposide 120 mg/m2 d1-3)
Study: 1910957
Drug: Intermittent cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclic etidronate (400 mg/day oral for 2 weeks, followed by 13 weeks off treatment)
Study: 1910957
Drug: ADFR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADFR treatment (100 micrograms/day oral triiodothyronine for 7 days, followed by 400 mg/day etidronate for 2 weeks and 12 weeks off treatment)
Study: 20977850
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg, once a day for 3-8 days
Study: 20977850
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 0.4 ml, twice a day for 3-8 days
Study: 15700050
Drug: Goserelin ('Zoladex')
Normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin ('Zoladex') injection using 16-gauge needle
Study: 15700050
Drug: Leuprorelin ('Prostap')
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin ('Prostap') injection using 23-gauge needle
Study: 15700050
Drug: Goserelin ('Zoladex')
Normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin ('Zoladex') injection
Study: 15700050
Drug: Leuprorelin ('Prostap')
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin ('Prostap') injection
Study: 12581262
Drug: Amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (200 mg intravenous infusion)
Study: 10479672
Drug: Fluindione plus
Normalized name: fluindione
DrugBank: Fluindione (DB13136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluindione plus aspirin (325 mg/d)
Study: 10479672
Drug: Fluindione plus
Normalized name: fluindione
DrugBank: Fluindione (DB13136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluindione plus aspirin
Study: 1624004
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration (2,500 U two times weekly between the 4th and 8th week of gestation)
Study: 1624004
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration in hMG/hCG generated gestations
Study: 1624004
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration in CC/hCG-induced pregnancies
Study: 1624004
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration in spontaneous conceptions
Study: 6342220
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange on six consecutive days at a mean exchange volume of 40.6 ml/kg of body weight each day
Study: 31457091
Drug: Gluten peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten peptide injection
Study: 29702502
Drug: Peri‐operative oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri‐operative oral caffeine (400 mg every 8 h for 2 days)
Study: 25237116
Drug: CBD 75
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 750]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 75 mg/day
Study: 22261900
Drug: brief monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: brief monthly CPR practice with voice‐activated manikins
Study: 15979768
Drug: Single morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single morning dose (400 ml) of carbohydrate-rich drink (CL)
Study: 15979768
Drug: Overnight fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight fasting (CC)
Study: 15979768
Drug: Single evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single evening dose (800 ml) of carbohydrate-rich drink (LC)
Study: 10518228
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptives with different progestogen types (desogestrel, gestodene, levonorgestrel, norgestimate) and ethinyl estradiol doses (50, 30, and 20 micrograms)
Study: 8198904
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 300 micrograms, 1 h before and 12 h after surgery
Study: 8198904
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine and placebo
Study: 29655700
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination containing fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols
Study: 24297318
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT‐based intervention)
Study: 18657134
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of lactose
Study: 16188753
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume packed red blood cell (PRBC) transfusions (20 ml/kg)
Study: 16188753
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume packed red blood cell (PRBC) transfusions (15 ml/kg)
Study: 10341394
Drug: Filtration leukocytapheresis
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtration leukocytapheresis (LCP) therapy, performed 3 times with 1 week intervals between procedures.
Study: 27943220
Drug: Lorazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.1 mg/kg, to a maximum of 4 mg)
Study: 26931195
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (Department of Internal Medicine) (control)
Study: 19874051
Drug: Antibody self‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody self‐oriented immunoprobe on magnetic nanoparticles (MNPs)
Study: 19874051
Drug: BA‐mediated covalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA‐mediated covalent antibody immobilization
Study: 17497543
Drug: Health Realization
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Realization treatment
Study: 17497543
Drug: 12-Step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Step treatment
Study: 15018625
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (Botox®) injections
Study: 12390854
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEI)
Study: 12390854
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker or alpha-receptor blocker (Control)
Study: 9661601
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg sublingually)
Study: 9661601
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (25 mg i.v. bolus)
Study: 7631600
Drug: Coagulation monitoring
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation monitoring including single daily estimation of PTF1 + 2 (target range < 0.5 nmol/L) and FII activity (15% to 35%); adjustment of heparin and phenprocoumon dosages based on PTF1 + 2 and FII measurements.
Study: 7448680
Drug: Probucol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1 g per day)
Study: 30915633
Drug: HCAG chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCAG chemotherapy
Study: 30915633
Drug: FLAG chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG chemotherapy
Study: 24629480
Drug: Brief behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioral cessation treatment (1 in-person session and 3 phone calls)
Study: 24629480
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral cessation treatment (3 in-person sessions and 5 phone calls)
Study: 24629480
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (brief and intensive)
Study: 17537781
Drug: Levonorgestrel (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (1.5 mg)
Study: 11784873
Drug: Normal-calcium, low-animal-protein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-calcium, low-animal-protein, low-salt diet (30 mmol calcium, 52 g animal protein, 50 mmol sodium chloride)
Study: 9744372
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% applied once daily for 6 months
Study: 2916889
Drug: Once-daily normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily normal saline irrigation
Study: 29939302
Drug: Prebiotic (fructooligosaccharide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (fructooligosaccharide, FOS, 12 g/day)
Study: 29939302
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 12 g/day)
Study: 28812167
Drug: 5-aminolevulinic (5-ALA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolevulinic (5-ALA) followed by 595-nm pulsed dye laser therapy (5-ALA PDL)
Study: 28812167
Drug: 595-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595-nm pulsed dye laser therapy alone (PDL alone)
Study: 25842221
Drug: Injectable gentamicin
Normalized name: gentamicin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable gentamicin and oral amoxicillin for 7 days (group B)
Study: 25842221
Drug: Injectable procaine
Normalized name: procaine Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C)
Study: 25842221
Drug: Injectable gentamicin
Normalized name: gentamicin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D)
Study: 15126738
Drug: Semont maneuver,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semont maneuver, Flunarizine, No treatment
Study: 8281528
Drug: Nitrendipine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10‐20 mg twice daily)
Study: 8733038
Drug: Lisinopril (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10‐20 mg once daily)
Study: 3732378
Drug: Cibenzoline administered
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline administered 1 h prior to food
Study: 3732378
Drug: Cibenzoline administered
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline administered with a standard breakfast
Study: 3732378
Drug: Cibenzoline administered
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline administered 1 h after a standard breakfast
Study: 31567375
Drug: T-180 mg-24
Normalized name: 2,4,5-T DIMETHYLAMMONIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-180 mg-24 h
Study: 31567375
Drug: T-90 mg-24
Normalized name: 2,4,5-T DIMETHYLAMMONIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-90 mg-24 h
Study: 31567375
Drug: T-90 mg-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-90 mg-12 h
Study: 25092564
Drug: CPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT plus thalidomide (5 mg/kg)
Study: 25092564
Drug: CPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT plus thalidomide (8 mg/kg)
Study: 25092564
Drug: CPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT plus thalidomide (10 mg/kg)
Study: 25092564
Drug: CPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT plus thalidomide (all doses)
Study: 22610355
Drug: CPT‐11 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 at a fixed dose of 60 mg/m2
Study: 20455850
Drug: Iscador (mistletoe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador (mistletoe therapy)
Study: 18627327
Drug: Neoadjuvant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant cisplatin-based combination chemotherapy
Study: 10189982
Drug: Therapeutic community
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic community and community residences treatment environments
Study: 7584934
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (delapril)
Study: 7584934
Drug: Ca antagonist
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca antagonist
Study: 1691882
Drug: Morphatropin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphatropin (1 ml s.c.)
Study: 396336
Drug: Inactivated Port
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A)
Study: 396336
Drug: Neuraminidase-specific (Heq1N2Ch)
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B)
Study: 28013097
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Prequit Gum and In-Person Counseling
Study: 21217614
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 10 mg plus submucous local tramadol (50 mg diluted in 1 mL saline solution)
Study: 21217614
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 10 mg plus submucous local placebo (1 mL saline solution)
Study: 11730183
Drug: HFA flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HFA flunisolide 170 microg, twice daily
Study: 11730183
Drug: HFA flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HFA flunisolide 340 microg, twice daily
Study: 11730183
Drug: CFC flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CFC flunisolide (250, 500, or 1,000 microg, twice daily)
Study: 29405670
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% 5 mL on radial and median nerves at the elbow (dNB group)
Study: 27930564
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (DEX) 1 μg/kg over 10 minutes, followed by 0.5 μg/kg/h continuous infusion
Study: 19046248
Drug: Cranberry treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry treatment for 12 weeks
Study: 15010695
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day nicotine transdermal patch
Study: 15010695
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (15 and 30 mg/70 kg)
Study: 9550480
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (aCL) presence in patients with giant cell arteritis
Study: 8148435
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group) for chronic fatigue syndrome (CFS)
Study: 2459174
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80 at 2.4 mg/ml
Study: 2459174
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80 at 0.6 mg/ml
Study: 2459174
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80 at concentrations less than 0.6 mg/ml
Study: 29382813
Drug: Succinylated gelatin
Normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylated gelatin (12 ml/kg)
Study: 29382813
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium chloride hydroxyethyl starch 40 injection
Study: 27544892
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine Green (ICG) intravenous injection before carotid endarterectomy
Study: 19748249
Drug: Combination treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment: Carbohydrate restriction diet for 6 weeks followed by American Heart Association diet (50-55% CHO) for an additional 6 weeks
Study: 10639539
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg once per day orally)
Study: 9181442
Drug: Drip infusion
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip infusion
Study: 7694148
Drug: esc-BACOP (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: esc-BACOP (escalated doses of doxorubicin)